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ABSTRACT 
Proteasome inhibitors, used in cancer treatment for their pro-apoptotic effects, have anti-
inflammatory and anti-fibrotic effects on animal models of various inflammatory and fibrotic 
diseases. Their effects in cells from patients affected by either inflammatory or fibrotic 
diseases have been poorly investigated. Nasal polyposis is a chronic inflammatory disease of 
the sinus mucosa characterized by tissue inflammation and remodeling. We tested the 
hypothesis that proteasome inhibition of nasal polyp fibroblasts might reduce their 
proliferation and their inflammatory and fibrotic response. Accordingly, we investigated the 
effect of the proteasome inhibitor MG262 on cell viability and proliferation, and on the 
production of collagen and inflammatory cytokines, in nasal polyp and nasal mucosa 
fibroblasts obtained from surgery specimens. MG262 reduced the viability of nasal mucosa 
and polyp fibroblasts concentration- and time-dependently, with marked effects after 48 h of 
treatment. The proteasome inhibitor bortezomib provoked a similar effect. MG262-induced 
cell death involved loss of mitochondrial membrane potential, caspase-3 and poly (ADP-
ribose) polymerase activation, induction of c-Jun phosphorylation, and mitogen-activated 
protein kinase phosphatase-1 expression. Low concentrations of MG262 provoked growth 
arrest, inhibited DNA replication and retinoblastoma phosphorylation, and increased 
expression of the cell cycle inhibitors p21 and p27. MG262 concentration-dependently 
inhibited basal and TGF-β-induced collagen mRNA expression and IL-1β-induced production 
of IL-6, IL-8, MCP-1, RANTES and GM-CSF in both fibroblast types. MG262 inhibited IL-
1β/TNF-α-induced activation of NF-κB. We conclude that non-cytotoxic treatment with 
MG262 reduces the proliferative, fibrotic, and inflammatory response of nasal fibroblasts, 
whereas high MG262 concentrations induce apoptosis.  
JPET # 190710 
 5
INTRODUCTION 
The ubiquitin-proteasome system is a multi-subunit enzyme complex present in the 
nucleus and cytoplasm of all eukaryotic cells; it plays a central role in the selective 
degradation of intracellular proteins that regulate transcription, cell cycle, apoptosis, cell 
adhesion, inflammatory processes and angiogenesis (Adams, 2003). An inhibitor targeting the 
proteasome, namely bortezomib, was approved by the FDA for the treatment of 
relapsed/refractory multiple myeloma (Wang et al., 2006; Meiners et al., 2008). Its efficacy 
relies on its capacity to induce the apoptosis of cells (preferentially transformed cells), 
through mechanisms involving inhibition of nuclear factor (NF)-κB and induction of the c-
Jun-N-terminal kinase (JNK) pathway (Meiners et al., 2008). Owing to the key role of NF-κB 
in multiple inflammatory diseases, the use of proteasome inhibitors has been proposed as an 
anti-inflammatory strategy for treating non-neoplastic diseases (Wang et al., 2006; Meiners et 
al., 2008). They have been shown to reduce the inflammatory response in experimental 
animal models of hypertension (Ludwig et al., 2009), arthritis (Palombella et al., 1998; 
Yannaki et al., 2010), colitis (Schmidt et al., 2010), and asthma (Elliott et al., 1999). 
Proteasome inhibitors have also demonstrated anti-fibrotic effects on animal models of 
cardiac fibrosis (Meiners et al., 2004), muscle atrophy (Carmignac et al., 2011), and lung and 
skin fibrosis (Mutlu et al., 2012). 
However, none of the numerous studies undertaken, both in vitro and in vivo, has 
clearly established the concentrations of the proteasome inhibitor that affect cell/animal 
viability and modulate cell function. In fact, the effect of proteasome inhibition on cell 
viability in non-cancerous cells has scarcely been investigated and has often been overlooked 
in studies reporting anti-inflammatory or anti-fibrotic effects of proteasome inhibitors. 
Furthermore, the anti-proliferative, anti-inflammatory and anti-fibrotic potential of 
proteasome inhibitors and their underlying mechanisms in the cells of patients affected by 
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either inflammatory or fibrotic diseases has been poorly investigated. These cells may 
significantly differ from cancerous cells in this respect. 
Chronic rhinosinusitis with nasal polyps is a chronic inflammatory disease of the sinus 
mucosa characterized by both tissue inflammation and remodeling (Bachert et al., 2009). 
Nasal polyps reveal frequent epithelial damage, a thickened basement membrane, and an 
edematous stroma with abundant infiltration of inflammatory cells, predominantly activated 
eosinophils, and fibrotic foci. Nasal polyp fibroblasts are key producers of extra-cellular 
matrix proteins, such as collagens, as well as pro-inflammatory cytokines and chemokines. 
In addition to maintaining the tissue structure, collagens are involved in cell adhesion, 
chemotaxis and migration in processes of growth, differentiation, and wound healing, and 
also in many pathological states. All collagens have three polypeptide chains, known as α-
chains. There are at least 29 human collagen types, numbered from I to XXIX, which can be 
divided into several subfamilies on the basis of their supramolecular assemblies. Collagen 
types I, II and III, among others, are fibril-forming collagens (Myllyharju and Kivirikko, 
2004). Collagen I, synthesized as two procollagen chains α1 and α2, each encoded by 
separate genes, is a major component of the extra-cellular matrix. An altered profile of 
collagens has been reported in the airways of asthmatics (Burgess, 2009). Patients with nasal 
polyps and associated asthma have increased fibroblast proliferation and extracellular matrix 
deposition, and increased fibroblast differentiation into myofibroblasts (Pawliczak et al., 
2005). Collagens I and III are expressed by lung (Goulet et al., 2007) and nasal fibroblasts 
(Pujols et al., 2011), and their expression is induced by the pro-fibrotic stimulus transforming 
growth factor (TGF)-β.  
Nasal polyp fibroblasts also release a variety of cytokines, chemokines and other pro-
inflammatory mediators, including interleukin (IL)-6, IL-8, granulocyte/macrophage colony-
stimulating factor (GM-CSF), monocyte chemoattractant protein (MCP)-1, and regulated on 
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activation normal T cell expressed and secreted (RANTES), that recruit and activate 
inflammatory cells into the nasal polyp site, thus contributing to the perpetuation of 
inflammatory and fibrotic processes in the tissue (Xing et al., 1993; Pujols et al., 2011). 
Corticosteroids, the gold standard of nasal polyp treatment, are ineffective in some 
patients, who will require one or even several surgical operations to remove nasal polyps 
(Fokkens et al., 2007). Nasal polyps are, therefore, an optimal model for researching the 
etiology of chronic inflammatory airway diseases, as well as potential therapeutic treatments. 
In the current work, we tested the hypothesis that proteasome inhibition of nasal polyp 
fibroblasts might reduce their proliferation and also modulate their inflammatory and fibrotic 
response. To do this, we used nasal fibroblasts obtained from both patients with nasal polyps 
and asthma and control subjects to characterize the effects of proteasome inhibition on the 
inflammatory and fibrotic cellular response. More specifically, we aimed to examine the 
effect of the proteasome inhibitor MG262 – which, like bortezomib, is a boronic peptide acid 
that selectively and reversibly inhibits the chymotryptic activity of the proteasome – on cell 
viability and proliferation, and on the production of collagen and inflammatory cytokines in 
nasal polyp and nasal mucosa fibroblasts. 
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MATERIALS AND METHODS 
Reagents. Dulbecco's Modified Eagle's Medium (DMEM) was obtained from Lonza (Fisher 
Scientific, Pittsburgh, PA, USA) and fetal bovine serum (FBS) from Biological Industries 
(Kibbutz Beit Haemek, Israel). Trypsin-EDTA, penicillin, streptomycin, 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES), small interfering RNA (siRNA) and all other 
transfection reagents were purchased from Invitrogen (Life Technologies; Carlsbad, CA, 
USA), and amphotericin B from Bristol-Myers Squibb (Middlesex, UK). MG262 [Z-Leu-
Leu-Leu-B(OH)2], IκB kinase (IKK) inhibitor III (BMS-345541), SP600125, SB203580, 
U0126, wortmannin, and caspase inhibitor I [Z-Val-Ala-Asp(OMe)-CH2F, z-VAD-FMK] 
were obtained from Calbiochem (Merck Chemicals Ltd., Nottingham, UK), and bortezomib 
(Velcade) from Selleckchem (Houston, TX, USA). All drugs were dissolved in 
dimethylsulfoxide at least at 500 μM, and further diluted in cell culture medium. TGF-β, IL-
1β and tumor necrosis factor (TNF)-α were purchased from R&D Systems (Abingdon, UK). 
Pifithrin-α [2-(2-imino-4,5,6,7-tetrahydrobenzothiazol-3-yl)-1-p-tolylethanone, HBr] and all 
other reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Subjects. Human nasal mucosa was obtained from 9 subjects (44.6 (mean) ± 4.6 (SEM) yr; 5 
men) without any history of nasal or sinus disease who underwent nasal corrective surgery for 
turbinate hypertrophy or septal dismorphy. Nasal polyps were obtained from 12 patients (47.5 
(mean) ± 3.1 (SEM) yr; 5 men) with diagnosis of nasal polyposis and asthma undergoing 
functional endoscopic sinus surgery. None of the patients had suffered from upper respiratory 
infection for at least 2 weeks prior to surgery. The diagnosis of nasal polyposis and asthma 
was based on established criteria, as reported elsewhere (Pujols et al., 2011). All the subjects 
agreed to participate in the study, which was approved by the Ethics Committee of our 
Institution. 
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Fibroblast culture. Fragments (approximately 3 x 3 mm) of the nasal tissues were placed in 
6-well culture dishes in DMEM supplemented with 10% FBS, 100 U/ml penicillin, 100 μg/ml 
streptomycin, and 2 μg/ml amphotericin B, in a humidified atmosphere at 37ºC and 5% CO2. 
Fibroblasts were isolated from the tissue fragments through adhesion and migration on the 
plastic surface, and further characterized by immunostaining of cytokeratin and vimentin, as 
previously reported (Pujols et al., 2011). In all the experiments, cells were growth-arrested by 
incubation with serum-free medium for 18 to 24 h prior to drug incubation. The experiments 
were carried out between passages 4 and 8. 
Small interfering RNA silencing. Thirty to 50% confluent nasal fibroblasts were transfected 
with 20 nM of either c-Jun Silencer Select pre-designed siRNA (Part Number: 4392420) or 
Silencer Select negative control siRNA (Part Number: 4390843) duplexes in complex with 
lipofectamine RNAiMAX in OptiMem I (1.5 μl/well for 24-well plate, 7.5 μl/well for 6-well 
plate, or 15 μl/well for 6 cm dish). Medium was changed 18 h after transfection. Forty-eight 
hours after transfection, cells were incubated with MG262 (10 nM) for an additional 48 h. 
Trypan blue exclusion assay. Fibroblasts were transfected and treated with MG262 as 
indicated above. The cell culture supernatants were collected and the trypan blue dye solution 
(0,4%) was added to the cell suspensions. The total number of dead cells was determined with 
standard hemocytometer procedure. Dead cells were seen as blue (permeable to dye due to 
disruption of the cell membrane). 
Cell viability assays. Cells were plated in 96-well culture plates (1-2x103 cells/well). The 
following day, cells were growth-arrested as indicated above and incubated with cell medium 
supplemented with 0.5% FBS with/without the simultaneous addition of the proteasome 
inhibitor MG262 (0.1-1,000 nM) for 24, 48 and 72 h, or with the proteasome inhibitor 
bortezomib (0.1-1,000 nM) for 48 h. In some experiments, the caspase inhibitor z-VAD-FMK 
was added (50 μM) for 1 h prior to incubation with MG262. After treatment, cell viability was 
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determined using the colorimetric Cell Proliferation Kit II (XTT, Roche Diagnostics GmbH, 
Mannheim, Germany). This assay is based on the cleavage of the yellow tetrazolium salt XTT 
to form an orange formazan dye by metabolic active (viable) cells. Absorbance was measured 
on a microplate spectrophotometer at 490 nm. 
Analysis of mitochondrial membrane potential (ΔΨm). Fibroblasts were incubated with 
cell medium supplemented with 0.5% FBS with/without the simultaneous addition of MG262 
(50, 500 and 1,000 nM) for 24 h. After treatment, the cells were incubated with the 
fluorescent mitochondrial dye 3,3′-dihexyloxacarbocyanine iodide (DiOC6, 40 nM) for 30 
min at 37ºC. The cell culture supernatant was then collected and combined with the 
trypsinized (0.05% trypsin-0.02% EDTA) adherent cells. The cells were then centrifuged, 
resuspended in phosphate-buffered saline (PBS), and incubated for 15 min with a violet-
fluorescent reactive dye (Live/Dead fixable dead cell stain kit, Invitrogen). The percentages of 
viable cells and those exhibiting loss of DiOC6 uptake were finally determined by 
fluorescence activated cell sorting (FACS) with a FACSCantoII instrument (BD Biosciences, 
San Diego, CA, USA) and the data were analyzed using the FACSDiva software 6.1.2 (BD 
Biosciences). 
Cell cycle analysis. Fibroblasts were treated with cell medium supplemented with 5% FBS 
with/without the simultaneous addition of MG262 (10 nM) for 24 h. The cells were then 
trypsinized, washed with PBS, fixed/permeabilized in 70% ethanol (overnight at 4ºC), washed 
again with PBS, and incubated for 30 min at 37ºC in a staining solution containing 0.34 
mg/ml sodium citrate, 0.015 mg/ml propidium iodide and 0.3 mg/ml ribonuclease A. DNA 
content was then measured by FACS. 
Analysis of DNA replication. Fibroblasts were treated with cell medium supplemented with 
5% FBS with/without the simultaneous addition of MG262 (10 nM) for 22 h. Two hours 
before the end of treatment the non-radioactive thymidine nucleoside analogue 5-ethynyl-2´-
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deoxyuridine (EdU) was added to the cell cultures. The cells were then trypsinized, washed 
with PBS, fixed in 70% ethanol (1 h, -20ºC), washed in 1% BSA in PBS, permeabilized with 
Triton X-100, and processed for the analysis of EdU incorporation into DNA, using the Click-
iT EdU Flow cytometry Assay kit (Invitrogen) as indicated by the manufacturer. 
Collagen mRNA expression. Fibroblasts were plated in six-well culture plates (105 
cells/well) until sub-confluence, growth-arrested as indicated above and pre-incubated with 
cell medium without FBS and increasing concentrations of MG262 (1 to 50 nM) for 1 h. In 
some experiments, cells were incubated with 1 μM of the p53 inhibitor pifithrin-α in the 
absence or presence of MG262. TGF-β (5 ng/ml) was then added to the cell cultures and total 
RNA was extracted 24 h later using the RNeasy Mini kit (Qiagen). One microgram of total 
RNA was converted to cDNA using the High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems). The mRNA expression of collagens 1α1, 1α2, 3α1, and RNA 
polymerase II was analyzed by real-time PCR (7900HT Fast Real-Time PCR System, 
Applied Biosystems) using TaqMan Fast Universal PCR Master Mix and TaqMan Gene 
Expression Assays (Assay ID’s: Hs00164004_m1, Hs00164099_m1, Hs00164103_m1, 
Hs00172187_m1, Applied Biosystems). Collagen mRNA expression was normalized to the 
mRNA expression of the constitutive gene RNA polymerase II, as published elsewhere (Pfaffl 
et al., 2001). 
Cytokine production. Fibroblasts were plated in 24-well culture plates (3x104 cells/well) 
until sub-confluence, growth-arrested as indicated above and pre-incubated with cell medium 
supplemented with 10% charcoal-stripped FBS (csFBS, Invitrogen) in the absence or 
presence of increasing concentrations of MG262 (5 to 500 nM) for 1 h. In some experiments, 
cells were pre-incubated (1 h) with the IKK/NF-κB inhibitor BMS-345541 (10 μM), the JNK 
mitogen-activated protein kinase (MAPK) inhibitor SP600125 (20 μM), the p38 MAPK 
inhibitor SB203580 (10 μM), the MAPK kinase MEK1/2 inhibitor U0126 (10 μM), and the 
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phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) inhibitor wortmannin (1 μM). Cells 
were then stimulated with 10 ng/ml of IL-1β or TNF-α (R&D Systems) for 4 h. IL-6 and IL-8 
production in supernatants was measured by ELISA (DuoSet ELISA, R&D Systems). MCP-1, 
RANTES, and GM-CSF production in supernatants was measured using specific BD 
Cytometric Bead Array (CBA) Flex Sets (BD Biosciences) by FACS, following the 
recommendations of the manufacturer. Cytokine production (pg/ml) was corrected by cell 
number using the XTT assay. 
Western blot. Cells were lysed in a lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 
mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 1% NP-40 Igepal, 1 μg/ml leupeptin, 1 μg/ml 
aprotinin, 0.1 mM Na3VO4, 1 mM NaF, 1 mM dithiothreitol, 0.5 mg/ml Pefabloc, and 5 
mg/ml sodium deoxycholate. Cell extracts (20-30 μg) were electrophoresed in SDS-
polyacrylamide gels and transferred to nitrocellulose membranes. Membranes were pre-
incubated for 1 h at room temperature in T-TBS (10 mM Tris-HCl [pH 7.4], 150 mM NaCl, 
0.1% Tween 20) containing either 5% fat-free powdered milk or 5% BSA, and then incubated 
(overnight at 4ºC) with the primary antibodies against p27 (cat. # sc-528), total retinoblastoma 
(Rb, cat. # sc-102), cyclin D1 (cat. # sc-20044), total (cat. # sc-45) and phosphorylated 
(Ser63, cat. # sc-822) c-Jun, MAPK phosphatase (MKP)-1 (cat. # sc-370), peroxisome 
proliferator-activated receptor-γ (PPAR-γ, cat. # sc-7196) (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), p53 (Ab-5, cat. # MS-186, Thermo Scientific, Cheshire, UK), 
phosphorylated (Ser807/811) Rb (cat. # 9308), phosphorylated (Thr180/Tyr182) p38 MAPK 
(cat. # 9215), cleaved caspase-3 (cat. # 9661), cleaved poly (ADP-ribose) polymerase (PARP, 
cat. # 9546) (Cell Signaling, Beverly, MA, USA), p21 (Cat. # OP64), phosphorylated (Ser32) 
IκB-α (cat. # 400002, Calbiochem), and β-actin (cat. # A5441, Sigma). After washing with T-
TBS, the membranes were incubated with the appropriate peroxidase-conjugated secondary 
antibodies for 1 h at room temperature, washed, and finally visualized by enhanced 
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chemiluminescence reaction (SuperSignal West Pico, Invitrogen). Light emission was 
detected by a CCD camera (LAS-3000, Fujifilm). 
Immunocytochemistry. Fibroblasts were treated with cell medium supplemented with 10% 
csFBS in the absence or presence of 500 nM MG262 for 1 h, and then stimulated with TNF-α 
or IL-1β (100 ng/ml each) for 30 min. The cells were then fixed in 4% paraformaldehyde, 
permeabilized in 0.1% Triton X-100 - 1% BSA, incubated with anti-p65 antibody (Cat. # sc-
372, Santa Cruz), washed in PBS, incubated with secondary antibody conjugated to Alexa 
488, mounted in Prolong® Gold aqueous mounting medium (Molecular Probes) and 
visualized by fluorescence microscopy (DMI6000B, Leica Microsystems, Wetzlar, Germany). 
Photographs were taken with a Leica DF350 FX digital camera and processed using the LAS 
AF software (Leica). 
Statistical analysis. Results are expressed as median and 25th to 75th percentiles. Multiple 
comparisons, such as concentration-response experiments, were analyzed using one-way 
ANOVA with Tukey/Dunnett post hoc analysis if variables were normally distributed and had 
similar variances, the latter calculated using the Barlett’s test or the Levene’s test. If the 
variable distributions were not normal and/or had different variances, the Kruskal-Wallis with 
Dunn’s post hoc analysis was used instead. Similarly, comparisons between two groups were 
made with the t-test if data were normally distributed and had similar variances or the Mann-
Whitney U test if the variable distributions were not normal and/or had different variances. 
The concentration (nM) of drug that results in 50% inhibition (IC50) of the effect provoked by 
the stimulus was calculated with the GraphPad Prism software. Statistical analyses were 
performed with SPSS and GraphPad Prism software. Statistical significance was established 
as p < 0.05. 
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RESULTS 
Effect of MG262 on fibroblast viability. It is well known that the efficacy of proteasome 
inhibitors, in particular bortezomib, in cancer relies on their capacity to induce cell death 
(Meiners et al., 2008). However, the effect of proteasome inhibitors on cell viability in non- 
cancerous cells has been less widely investigated and remains controversial (Fineschi et al., 
2006; You and Park, 2011). In an attempt to discern the concentration and incubation time 
with the proteasome inhibitor MG262 that affect the viability of nasal fibroblasts, we carried 
out concentration-response and time-course experiments with the proteasome inhibitor 
MG262 and analyzed the viability of nasal fibroblasts thereafter by using the XTT metabolic 
assay. As shown in Figure 1A, the treatment of nasal fibroblasts with MG262 for 24 h 
provoked a significant concentration-dependent reduction in cell viability in both nasal 
mucosa and nasal polyp fibroblasts. The maximal suppression reached approximately 40% in 
both cases. A marked concentration-dependent decrease in cell viability was found after 48 h 
(Figure 1B) and 72 h (Figure 1C) of MG262 treatment. No differences in IC50 (median, nM; 
25th-75th percentiles) were found between nasal mucosa (48 h: 11; 10-23; 72 h: 4; 3-6) and 
nasal polyp fibroblasts (48 h: 7; 5-35; 72 h: 4; 3-8; ns). A significant decrease in cell viability 
was also found after 48 h of fibroblast treatment with the proteasome inhibitor bortezomib 
(Figure 1D). IC50 values for bortezomib did not either differ between nasal mucosa (36; 10-
191) and polyp fibroblasts (24; 17-67; ns). 
Effect of MG262 on apoptosis. Because we found that MG262 reduced the viability of nasal 
fibroblasts and proteasome inhibitors are known to provoke tumor cell death via the induction 
of apoptosis (Hideshima et al, 2001), we reasoned that the cell death of nasal fibroblasts 
provoked by MG262 would also involve apoptosis. The initial apoptotic pathways end at the 
point of the execution phase, considered the final pathway of apoptosis, where the activation 
of executioner caspases (of which caspase-3 is the most important) provokes the cleavage of 
JPET # 190710 
 15
various substrates, such as poly (ADP-ribose) polymerase (PARP), that ultimately cause the 
morphological and biochemical changes seen in apoptotic cells (Elmore, 2007). To elucidate 
whether MG262 induced nasal fibroblast apoptosis, fibroblasts were either pre-incubated with 
the caspase inhibitor z-VAD-FMK (50 μM) prior to incubation with MG262 or were not 
treated, and cell viability was analyzed by the XTT assay. As shown previously, incubation 
with high concentrations of MG262 for 48 h significantly reduced fibroblast viability 
compared to non-treated cells (Figure 2A). More importantly, z-VAD-FMK partially 
prevented the reduction of fibroblast viability provoked by MG262, suggesting that the 
decrease in cell viability provoked by long-term exposure with MG262 involves apoptosis. 
The loss of mitochondrial membrane potential is one of the earliest events that initiates 
the classical intrinsic pathway of apoptosis (Elmore, 2007) and proteasome inhibitors are 
known to induce this event in cancer cells (Ling et al., 2003b; Domingo-Domènech et al., 
2008). We therefore aimed to investigate whether MG262 provoked the loss of mitochondrial 
membrane potential in nasal fibroblasts. As shown in Figure 2B, incubation of fibroblasts 
with MG262 for 24 h caused a significant concentration-dependent loss of mitochondrial 
membrane potential. We then explored whether MG262 provoked the activation of caspase-3 
and that of its substrate PARP in nasal fibroblasts, as occurs after proteasome inhibition of 
tumor cells (Hideshima et al., 2001; Ling et al., 2003a; Ling et al., 2003b). Treatment with 50 
nM MG262 for 24 h did not result in the expression of cleaved caspase-3, or its substrate 
PARP, in any fibroblast line (Figure 2C). At 24 h, expression of cleaved caspase-3 was only 
found at the highest concentration of MG262 (1,000 nM). Expression of cleaved caspase-3 
and PARP was detected after cell incubation with 50 nM MG262 for 48 h (Figure 2C).  
Induction of the JNK MAPK stress pathway is another reported mechanism by which 
proteasome inhibitors provoke apoptosis of tumor cells (Meiners et al., 2008; Hideshima et 
al., 2003; Yang et al., 2004). The activity of JNK and other MAPK is endogenously 
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controlled by different MAPK phosphatases, such as MKP-1 (Liu et al., 2007). MKP-1 is 
degraded through the proteasome and is known to be activated by proteasome inhibitors in 
cancer cells (Small et al., 2004). We hypothesized that MG262 would also activate the JNK 
pathway and MKP-1 in nasal fibroblasts. Accordingly, treatment of nasal fibroblasts with 
MG262 (50 nM) markedly induced c-Jun phosphorylation 6 and 24 h after administration 
(Figures 3A and 3B, upper graph), and also induced MKP-1 expression (Figures 3A and 3B, 
lower graph). We then examined the involvement of c-Jun activation on the pro-apoptotic 
effect of MG262 on our cells by silencing c-Jun expression using small interfering RNA 
(siRNA) techniques. We first demonstrated that MG262-induced c-Jun phosphorylation was 
abrogated in c-Jun siRNA-transfected cells (Figure 3C). Interestingly, the induction of cell 
death provoked by the exposure of nasal fibroblasts to 10 nM MG262 for 48 h was 
significantly abrogated in c-Jun siRNA-transfected cells (Figure 3D and 3E), which indicates 
that the increase in cell death provoked by long-term exposure with MG262 involves 
activation of the JNK/c-Jun pathway. 
Effect of MG262 on the cell cycle. Exposure of cancer cells to proteasome inhibitors causes 
cell-cycle arrest (Codony-Servat et al., 2006; Ling et al., 2003a; Domingo-Domènech et al., 
2008). We investigated whether MG262 also caused cell-cycle arrest in nasal fibroblasts. As 
expected, the treatment of growth-arrested fibroblasts with a cell growth stimulus, i.e. 5% 
FBS, markedly increased the S phase and G2/M population and, consequently, decreased the 
G0/G1 population (Figure 4A and Table 1). MG262 (10 nM), added simultaneously to the 
stimulus, provoked the complete arrest of cell cycle progress compared to 5% FBS-treated 
cells. Thus, MG262-treated cells had a percentage of cells in G0/G1, S and G2/M similar to 
that of FBS-deprived cells, indicating that MG262 did not allow cells to progress into the S 
phase. At this concentration, MG262 did not significantly increase the sub-G0/G1 population 
associated with cell death, compared to both FBS-deprived and 5% FBS-treated cells (Figure 
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4A). MG262 caused cell accumulation at S and G2/M in asynchronized (non-growth-arrested) 
cell cultures (data not shown). Confirming the propidium iodide staining findings (Figure 
4A), MG262 (10 nM) completely abolished cell proliferation (DNA replication), the 
percentage of proliferating cells being similar to that of FBS-deprived cells (Figure 4B and 
Table 1). 
Progression through the G1 cell-cycle restriction point is controlled by the 
phosphorylation status of retinoblastoma (Rb). Rb phosphorylation induced by cyclin-cyclin-
dependent kinase (CDK) complexes (cyclin D-CDK4/6 first, followed by cyclin E-CDK2) 
provokes Rb inactivation, thus permitting the release of the transcription factor E2F and cell-
cycle progression (Poznic et al., 2009). CDK activity is negatively regulated by CDK 
inhibitors, including p21 and p27 (Sherr et al., 1999). Since we found that MG262 provoked a 
cell-cycle arrest of nasal fibroblasts that did not allow cells to progress into the S phase, we 
hypothesized that some of the cell-cycle proteins that regulate the G1-S transition might be 
affected by MG262. As expected, the incubation of nasal fibroblasts with 5% FBS for 6 h, 
and more particularly for 24 h, provoked hyperphosphorylation of Rb compared to serum-
deprived cells (Figures 5A and 5B). MG262 treatment, even at the lowest concentration tested 
(5 nM), completely inhibited Rb phosphorylation, in keeping with the findings of the 
blockade of cell cycle progression by MG262 (Figure 4). In addition, the incubation of 
fibroblasts with 5% FBS for 6 h significantly increased the expression of the positive 
regulatory cell-cycle protein cyclin D1, and MG262 increased (without statistical 
significance) cyclin D1 expression, compared to FBS-treated cells (Figure 5C). MG262 also 
provoked a time- and concentration-dependent increase in the expression of the cell-cycle 
inhibitors p21, and to a lesser extent that of the p27 (Figures 5D and 5E). 
Effect of MG262 on collagen mRNA expression. Once the effect of MG262 on the cell 
cycle and viability of nasal fibroblasts had been characterized, we aimed to determine the 
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capacity of MG262 to modulate, and more specifically to decrease, their fibrotic and 
inflammatory response. One of the first studies assessing the anti-fibrotic potential of 
proteasome inhibitors reported a decrease in collagen mRNA expression after proteasome 
inhibition of human dermal fibroblasts (Fineschi et al., 2006). We therefore investigated 
whether MG262 also reduced collagen expression in nasal fibroblasts. In agreement with our 
previous studies (Pujols et al., 2011), the pro-fibrogenic stimulus TGF-β (5 ng/ml) induced 
the mRNA expression of collagens 1α1, 1α2 and 3α1 in both nasal mucosa and polyp 
fibroblasts (Figure 6A). No significant differences were found between nasal mucosa and 
polyp fibroblasts as regards the extent of mRNA induction by TGF-β of the three collagen 
types. MG262 provoked a concentration-dependent decrease in the TGF-β-induced mRNA 
expression of the three collagen types in both nasal mucosa and polyp fibroblasts (Figure 6A). 
At 50 nM, MG262 inhibited the mRNA expression of all three collagens more than the basal 
condition (no TGF-β). Indeed, as shown in Figure 6B, MG262 also markedly suppressed the 
basal expression of collagens.  
 We then attempted to elucidate the mechanisms by which MG262 suppressed collagen 
mRNA expression in nasal fibroblasts. We have already demonstrated that MG262 increased 
c-Jun phosphorylation induced by 5% FBS (Figure 3A and 3B). Previous reports have shown 
that stimulation of the JNK/activator protein (AP)-1 pathway by phorbol 12-myristate 13-
acetate or estradiol leads to the suppression of type I collagen synthesis (Silbiger et al., 1999). 
Based on these observations, we hypothesized that MG262 would also increase c-Jun 
phosphorylation induced by TGF-β, and that such an increase might partly explain the 
suppressive effect of MG262 on collagen expression in our cells. As shown in Figure 6C, 
MG262 markedly increased c-Jun phosphorylation in both basal and TGF-β-stimulated nasal 
fibroblasts. To elucidate whether this induced c-Jun phosphorylation was involved in the 
suppression of collagen expression by MG262, we analyzed the effect of MG262 in cells with 
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a silenced expression of c-Jun. The suppression of TGF-β-stimulated collagen mRNA 
expression by MG262 was not abrogated, however, in c-Jun siRNA-transfected nasal 
fibroblasts (data not shown).  
The gene expression of type I collagen induced by TGF-β is primarily mediated via 
the Smad signaling pathway, where, after phosphorylation by the activated type I TGF-β 
receptor, cytoplasmic Smad2 and Smad3 heterodimerize with Smad4 and accumulate within 
the nucleus, where they recruit cofactors to Smad-binding elements in the collagen gene 
promoter and thereby activate collagen transcription (Ghosh, 2002). One of the numerous 
proteins found to repress TGF-β-induced collagen gene expression is the nuclear hormone 
receptor PPAR-γ (Ghosh et al., 2009). It has recently been reported that bortezomib inhibits 
TGF-β-mediated target gene expression in lung fibroblasts, partly by increasing PPAR-γ 
abundance and activity (Mutlu et al., 2012). We expected that MG262 would similarly 
increase PPAR-γ protein levels in nasal fibroblasts but it failed to do so in both basal and 
TGF-β-stimulated nasal fibroblasts (Figure 6C).  
The tumor suppressor p53 has also been reported as a potent repressor of TGF-β-
regulated collagen gene expression in fibroblasts (Ghosh et al., 2004; Nacu et al., 2008). 
Proteasome inhibitors are known to up-regulate the expression of p53 in multiple myeloma 
cells (Hideshima et al., 2003). We therefore hypothesized that MG262 would increase p53 
levels in nasal fibroblasts, and that such an increase may partly explain the suppressive effect 
of MG262 on collagen expression. As shown in Figure 6C, MG262 increased p53 levels in 
both basal and TGF-β-stimulated nasal fibroblasts. To elucidate whether this increase in p53 
was involved in the suppression of collagen expression by MG262, we analyzed the capacity 
of MG262 to suppress collagen mRNA expression in cells whose p53 activity was inhibited 
by cell treatment with 1 μM of the p53 inhibitor pifithrin-α. MG262 still markedly inhibited 
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both basal and TGF-β-stimulated collagen mRNA expression in pifithrin-α-treated fibroblasts 
(supplementary Figure 1).  
Effect of MG262 on the production of pro-inflammatory cytokines. In order to determine 
the anti-inflammatory potential of proteasome inhibition in nasal fibroblasts, we first 
investigated the effect of MG262 on the production of the pro-inflammatory cytokines IL-6 
and IL-8, which are released in high amounts by these cells (Pujols et al., 2011). As expected, 
the treatment of cells with 10 ng/ml of the pro-inflammatory stimuli IL-1β (Figure 7A) or 
TNF-α (supplementary Figure 2) for 4 h markedly induced IL-6 and IL-8 production in both 
nasal mucosa and polyp fibroblasts, compared to non-stimulated cells. MG262 concentration-
dependently inhibited IL-1β-induced IL-6 and IL-8 production in both fibroblast types (Figure 
7A). MG262 also inhibited TNF-α-induced IL-6 and IL-8 production in both fibroblast types, 
although inhibition did not reach statistical significance for IL-6 (supplementary Figure 2). 
Under the conditions tested in this study, MG262 did not significantly alter cell viability, as 
determined by the XTT assay, compared to non-MG262-treated cells (data not shown).  
We then aimed to elucidate the mechanisms by which MG262 could inhibit IL-1β-
induced IL-6 and IL-8 release in nasal fibroblasts. The main proposed mechanism by which 
proteasome inhibitors reduce the release of a variety of pro-inflammatory mediators is 
through inhibition of NF-κB (Meiners et al, 2008). Nevertheless, we first determined the 
intracellular signaling pathways involved in IL-1β-induced IL-6 and IL-8 release. The release 
of IL-6 and IL-8 induced by IL-1β was completely abrogated by the pre-treatment of nasal 
fibroblasts with the IKK/NF-κB inhibitor BMS-345541, and inhibited to a lesser extent by the 
p38 and JNK MAPK inhibitors SB203580 and SP600125, respectively (Figure 7B). 
Consequently, we first explored whether cytokine inhibition by MG262 involved reduced NF-
κB activation. MG262 prevented the translocation of the NF-κB subunit p65 to the cell 
nucleus induced by both IL-1β (Figure 7C) and TNF-α (supplementary Figure 3), and also 
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prevented the degradation of p-IκBα in IL-1β-stimulated fibroblasts (Figure 7D). In addition, 
treatment of cells with MG262, under the same experimental conditions that inhibited IL-6 
and IL-8 release (Figure 7A), increased the phosphorylation of p38 and c-Jun MAPK in both 
basal and IL-1β-stimulated fibroblasts (Figure 7E). Therefore, the inhibitory effect of MG262 
on cytokine release does not occur through inhibition of either c-Jun or p38 MAPK.  
Finally, we determined whether the inhibitory effects of MG262 on IL-6 and IL-8 
production also occurred for other pro-inflammatory cytokines and chemokines, more 
specifically MCP-1, RANTES and GM-CSF. These molecules are secreted by nasal 
fibroblasts upon exposure to different proinflammatory or stressful stimuli and they are 
known to participate in the recruitment and activation of monocytes, lymphocytes, or 
eosinophils to the inflammatory site (nasal polyp) (Xing et al., 1993; Meyer et al., 1998; 
Nonaka et al., 1999; Le Bellego et al., 2009). MG262 provoked a significant concentration-
dependent decrease in the IL-1β-induced production of MCP-1, RANTES and GM-CSF in 
nasal mucosa and polyp fibroblasts (Figure 8). 
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DISCUSSION 
This is the first study to assess the effect of proteasome inhibition on the proliferation 
and regulation of the cell’s function in primary airway fibroblasts – in this case nasal 
fibroblasts – from both control subjects and patients with airway inflammatory diseases (in 
this case nasal polyposis and asthma). 
Using the XTT assay, we first found that MG262 reduced the viability of nasal 
fibroblasts, especially after 48 and 72 h of treatment. Cell viability was similarly reduced by 
the exposure of nasal fibroblasts to bortezomib. Proteasome blockade was as effective in nasal 
polyp as in control nasal mucosa fibroblasts. The kinetics and sensitivity (IC50) of MG262 and 
bortezomib inhibition was similar to those reported for bortezomib in cancer cell lines 
(Hideshima et al., 2001; Codony-Servat et al., 2006). Our results concur with those reported 
in human pulmonary fibroblasts using the proteasome inhibitor MG132 (You and Park, 2011) 
and in bortezomib-treated rat fibroblast-like synoviocytes (Yannaki et al., 2010), but contrast 
with those of Fineschi and coworkers (Fineschi et al., 2006 and 2008). The latter, using a 
similar experimental approach and analytical method, found that MG262 and proteasome 
inhibitor I decreased the viability of human dermal fibroblasts only when used at very high 
(micromolar) concentrations after 72 h of culture (Fineschi et al., 2006). This suggests that the 
sensitivity to MG262-induced cell death would depend on the fibroblast origin, i.e., nose 
versus skin. These authors then reported that exposure of murine lung fibroblasts to 1 μM 
bortezomib for 24 h similarly had no effect on cell viability (Fineschi et al., 2008), which 
contrasts with the inhibitory effect of MG262 on nasal fibroblast viability when used at an 
equivalent time and concentration.  
MG262 provoked the loss of mitochondrial membrane potential in nasal fibroblasts, 
thus confirming that the decrease in cell viability by MG262 was due to the induction of 
apoptosis. The induction of this early apoptotic event by proteasome inhibitors has been 
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reported in cancer cells (Ling et al., 2003b; Domingo-Domènech et al., 2008) and also in 
human pulmonary fibroblasts (You and Park, 2011). Our results using the caspase inhibitor z-
VAD-FMK revealed that the decrease in nasal fibroblast viability provoked by MG262 
involved caspase-mediated apoptosis. Accordingly, and in agreement with studies in 
cancerous (Hideshima et al., 2001; Ling et al., 2003a; Ling et al., 2003b) and non-cancerous 
cells (Kawakami et al., 1999; Goldbaum et al., 2006), MG262 induced the activation of the 
apoptotic enzymes caspase-3 and PARP in nasal fibroblasts. However, compared to cancer 
cell lines, these enzymes appear to be much less activated by proteasome inhibition in our 
cells, thus requiring very high concentrations of MG262 (1,000 nM) for at least 24 h to be 
detected. This may be because nasal fibroblasts are more resistant to proteasome inhibitor-
mediated apoptosis than other cell types, or because proteasome inhibitor-mediated apoptosis 
in our cells primarily involves apoptotic mediators other than caspase-3 and PARP. 
In line with studies reported in tumor cells (Hideshima et al., 2003; Yang et al., 2004), 
MG262 provoked a strong activation (phosphorylation) of c-Jun in nasal fibroblasts. The 
involvement of c-Jun activation in MG262-induced cell death was further demonstrated in 
transfection experiments with c-Jun siRNA. MG262 also activated MKP-1 expression in our 
cells. The induction of MKP-1 by proteasome inhibitors is reported to play an anti-apoptotic 
role through down-regulation of JNK activity (Small et al., 2004). Effectively, the over-
expression of MKP-1 in cancer is reported to be a bad prognostic factor for curing the disease 
(Small et al., 2007). In our fibroblasts, MG262-induced MKP-1 expression does not appear to 
down-regulate c-Jun activity, as the phosphorylation of c-Jun was strongly induced by 
MG262, but a possible relationship between these two events has not been investigated. 
Conversely, the current study has not explored whether inhibition of MKP-1 would further 
enhance the JNK pathway and, as a result, increase the apoptotic capacity of MG262. 
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Proteasome inhibitors cause cell-cycle arrest, particularly a G2/M arrest, in cancer 
cells (Codony-Servat et al., 2006; Ling et al., 2003a; Domingo-Domènech et al., 2008). The 
use of synchronized (growth-arrested) cultures showed that this arrest takes place not only in 
G2/M but also in G0, G1 or G1/S transition in nasal fibroblasts. In keeping with the blocking 
effects of MG262 on the cell cycle, MG262 inhibited the proliferation (DNA replication) of 
nasal fibroblasts. These results concur with the marked inhibition of cell proliferation after the 
incubation of fibroblast-like synoviocytes with bortezomib, at the same concentration (10 nM) 
used in our study (Yannaki et al., 2010).  
MG262 inhibited Rb phosphorylation and, in agreement with data reported in 
cancerous cells (Hideshima et al., 2001; Ling et al., 2003a; Codony-Servat et al., 2006), 
increased the expression of p21 and p27 in nasal fibroblasts. Since p21 and p27 are well-
known proteasome substrates (Adams et al., 2003), their increase by MG262 is most probably 
the result of their inhibited degradation. The increase in cyclin D1 levels after fibroblast 
treatment with MG262 is unsurprising because cyclin D1 is also degraded by the proteasome 
(Guo et al., 2005). Therefore, the lack of Rb phosphorylation, and consequently the inhibition 
of cell-cycle progression, provoked by MG262 in nasal fibroblasts must be the consequence 
of increased p21 and p27 rather than any lack of cyclin D1. 
We have explored the capacity of MG262 to down-regulate the pro-fibrotic function of 
nasal fibroblasts. We previously reported that TGF-β induced the mRNA expression of 
collagen types 1α1, 1α2 and 3α1 in nasal fibroblasts – an induction not abrogated by 
glucocorticoid treatment (Pujols et al., 2011). We now report that moderately low 
concentrations of MG262 (10-50 nM) significantly reduce the mRNA expression of the three 
collagen types in both unstimulated and TGF-β-stimulated nasal mucosa and polyp 
fibroblasts. Similarly, a decrease in collagen mRNA expression has been reported after 
proteasome inhibition of human dermal (Fineschi et al., 2006; Goffin et al., 2010) and murine 
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lung fibroblasts (Fineschi et al., 2008). Proteasome inhibition in rat cardiac fibroblasts also 
decreased collagen mRNA expression and expression of matrix metalloproteinases 2 and 9 
(Meiners et al., 2004). It has recently been reported that bortezomib inhibits TGF-β-mediated 
target gene expression in human lung fibroblasts from normal individuals and patients with 
idiopathic pulmonary fibrosis, and in skin fibroblasts from a patient with scleroderma (Mutlu 
et al., 2012).  
The mechanisms by which proteasome inhibitors suppress collagen expression have 
not been fully elucidated. Numerous transcription factors and cofactors are known to be 
involved in the regulation of both basal and TGF-β-stimulated type I collagen gene 
expression, including, among others, SP1, AP-1, different Smad family members, CBP/p300, 
PPAR-γ, and p53 (Ghosh, 2002; Ghosh et al., 2009). As opposed to results reported in lung 
fibroblasts (Mutlu et al., 2012), PPAR-γ levels were not increased by exposure of nasal 
fibroblasts to MG262. We found that MG262 increased c-Jun phosphorylation and p53 levels 
in both unstimulated and TGF-β-stimulated nasal fibroblasts, but none of these effects could 
explain the marked suppressive effect of MG262 on collagen expression. With regard to other 
transcription factors involved in TGF-β-induced collagen expression, Goffin and coworkers 
(2010) reported that bortezomib did not affect TGF-β-induced Smad2 phosphorylation, 
nuclear translocation, or binding to the collagen 1α2 promoter. In fact, Fineschi and 
coworkers (2008) reported an increase in TGF-β-induced Smad2 phosphorylation by 
proteasome inhibitors. Mutlu and coworkers (2012) similarly found that bortezomib did not 
inhibit TGF-β-induced Smad3 phosphorylation or nuclear translocation, although it inhibited 
the transcription of a Smad-responsive luciferase reporter construct. It is worth noting that 
bortezomib abrogated the binding of SP1 to the collagen 1α2 promoter in both untreated and 
TGF-β-stimulated fibroblasts (Goffin et al., 2010). Analysis of the possible role of SP1 will 
be the subject of future experiments but are beyond the scope of the current manuscript. 
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We have also explored the capacity of MG262 to regulate the production of pro-
inflammatory cytokines and chemokines by nasal fibroblasts. MG262 reduced the IL-1β- and 
TNFα-induced release of IL-6 and IL-8 by both nasal mucosa and polyp fibroblasts. In 
agreement with our results, a decrease in IL-6 production has been reported after proteasome 
inhibition of TNF-α-stimulated airway smooth muscle cells (Moutzouris et al., 2010), LPS 
plus phorbol 12-myristate 13-acetate-stimulated U937 monocytes (Ortiz-Lazareno et al., 
2008), and multiple myeloma cell lines (Hideshima et al., 2001). Controversial results have 
been obtained with regard to IL-8: in line with our results, proteasome inhibition of LPS-
stimulated macrophages has led to decreased IL-8 levels (Cuschieri et al., 2004), but 
increased IL-8 levels have also been reported after the proteasome inhibition of various cell 
types (Hipp et al., 2002; Gerber et al., 2004). MG262 also decreased the IL-1β-induced 
production of other pro-inflammatory mediators, i.e., MCP-1, RANTES and GM-CSF, known 
to participate in the recruitment and activation of inflammatory cells on the nasal polyp site 
(Xing et al., 1993; Meyer et al., 1998; Nonaka et al., 1999; Le Bellego et al., 2009). The 
inhibition of one or more of these mediators by proteasome inhibitors has also been reported 
in human airway smooth muscle (Moutzouris et al., 2010) and endothelial cells (Hipp et al., 
2002). 
The potent anti-inflammatory effects of proteasome inhibitors have been mainly 
attributed to attenuated activation of the pro-inflammatory transcription factor NF-κB 
(Meiners et al, 2008). Our experiments using intracellular pathway-specific inhibitors 
revealed that activation of NF-κB is critical in the induction of IL-6 and IL-8 production by 
IL-1β in nasal fibroblasts. Although we did not directly demonstrate this, NF-κB is also likely 
to be critical in the induction of MCP-1, RANTES and GM-CSF by IL-1β in nasal fibroblasts, 
since the expression of these genes is also regulated by NF-κB (Barnes and Karin, 1997). 
Interestingly, and in line with previous studies (Palombella et al., 1998; Codony-Servat et al., 
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2006), MG262 blocked the IL-1β-stimulated activation of NF-κB in nasal fibroblasts via two 
distinct mechanisms: firstly by preventing the degradation of the NF-κB inhibitor IκBα, and 
secondly by impairing IL-1β/TNF-α-induced translocation of NF-κB to the cell nucleus. 
In summary, our study shows that the proteasome inhibitor MG262, when 
administered at high concentrations or for long exposure times, provokes the cell death of 
primary nasal mucosa and polyp fibroblasts via the induction of apoptosis, by involving the 
expression of cleaved caspase-3 and PARP, and phosphorylation of c-Jun. Lower 
concentrations of MG262 block the progression of the cell cycle, by involving the inhibition 
of Rb phosphorylation and an increase in the cell-cycle inhibitors p21 and p27. MG262 
inhibits the functional activity of nasal fibroblasts by reducing both basal and TGF-β-induced 
expression of collagens and also by down-regulating the production of IL-6, IL-8, MCP-1, 
RANTES and GM-CSF induced by pro-inflammatory stimuli. The MG262-mediated 
inhibition of pro-inflammatory cytokine production involves the inactivation of NF-κB. In 
conclusion, non-cytotoxic treatment with MG262 reduces the proliferative, fibrotic, and 
inflammatory response of nasal fibroblasts, whereas high MG262 concentrations induce 
apoptosis. The current study provides evidence of the effect of a proteasome inhibitor and its 
action mechanisms in a human in vitro cell culture model. Caution is required, however, 
before proposing proteasome inhibition as an alternative therapeutic strategy for reducing 
inflammation and fibro-proliferation in airway inflammatory diseases such as chronic asthma 
or nasal polyposis. In this respect, the anti-fibrotic and anti-inflammatory effects of 
proteasome inhibitors should be demonstrated in other cell types and, more importantly, 
proteasome inhibitors should be tested in vivo in animal models of the disease, with especial 
attention to the apoptotic-inducing effects of these drugs. 
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FIGURE LEGENDS 
Figure 1. Effect of MG262 on nasal fibroblast viability. Nasal mucosa (continuous lines) and 
nasal polyp (dashed lines) fibroblasts were incubated with DMEM supplemented with 0.5% 
FBS with/without the simultaneous addition of MG262 for (A) 24 h, (B) 48 h, or (C) 72 h, or 
with bortezomib for 48 h (D). Cell viability was then determined by measuring (490 nm) the 
formation of a soluble formazan salt by metabolic active (viable) cells using the XTT assay. 
Data represent the median and interquartile range of at least n= 5 independent experiments 
from different patients. *p< 0.05 vs untreated cells. 
 
Figure 2. Effect of MG262 on nasal fibroblast apoptosis. (A) Fibroblasts were incubated with 
DMEM supplemented with 0.5% FBS with or without z-VAD-FMK (50 μM) for 1 h prior to 
MG262 exposure for 48 h. Cell viability was measured by the XTT assay as indicated in 
Figure 1. *p< 0.01 vs 0% FBS; †p< 0.001 vs 0.5% FBS; #p< 0,01 vs z-VAD-FMK. (B) 
Fibroblasts were incubated with 0.5% FBS-supplemented DMEM with/without the 
simultaneous addition of MG262 for 24 h. Cells were then incubated with the fluorescent 
mitochondrial dye DiOC6 (40 nM), stained with a violet-fluorescent reactive dye (Live/Dead 
fixable dead cell stain kit) and the percentages of viable cells exhibiting loss of mitochondrial 
membrane potential (ΔΨm) determined by FACS. *p< 0.05 compared to untreated (C) cells. 
Graphs A and B show the median (bars) and interquartile range (whiskers) of n= 5 
independent experiments from different patients. (C) Fibroblasts were incubated with 0.5% 
FBS-supplemented DMEM with/without the simultaneous addition of MG262 for 24 and 48 
h. Cellular lysates were then obtained, electrophoresed on SDS-polyacrylamide gels, 
transferred to nitrocellulose membranes, and membranes incubated with primary antibodies 
against cleaved caspase-3, PARP and β-actin. Images are representative Western blots of n= 3 
independent experiments from different patients.  
JPET # 190710 
 39
 
Figure 3. Involvement of c-Jun in MG262-mediated nasal fibroblast cell death. (A) 
Fibroblasts were incubated with DMEM supplemented with 5% FBS with/without the 
simultaneous addition of MG262 for 6 and 24 h. Cellular lysates were then obtained, 
electrophoresed on SDS-polyacrylamide gels, transferred to nitrocellulose membranes, and 
membranes incubated with primary antibodies. Images are representative Western blots of 
phosphorylated c-Jun, total c-Jun, MKP-1 and β-actin. The 42 kDa band detected in MKP-1 
Western blots is a non-specific band, supposedly, MKP-2. (B) Quantification of p-c-Jun and 
MKP-1 Western blots of the time-course experiments with MG262 shown in A. **p<0.01 and 
***p<0.001 vs 5% FBS. (C-E) Fibroblasts were transfected with 20 nM of c-Jun siRNA or a 
negative control siRNA using lipofectamine RNAiMAX, as indicated in Materials and 
Methods. Forty-eight hours after transfection, cells were incubated with MG262 (10 nM) for 
48 h. (C) Cellular lysates of adhered cells were then obtained and analyzed for the 
immunodetection of p-c-Jun and β-actin by Western blot. (D) The viability of c-Jun or 
negative control siRNA-transfected fibroblasts was measured by the XTT assay as indicated 
in Figure 1; *p<0.05. (E) The cell culture supernatants of the experiments shown in C were 
collected and the number of dead cells counted by the Trypan-blue dye exclusion method; 
*p<0.05. Results shown in A and B and C to E are derived from n= 7 and n= 4 independent 
experiments from different patients, respectively. All graphs show the median (bar) and 
interquartile range (whiskers). 
 
Figure 4. Effect of MG262 on nasal fibroblast cell cycle. (A) Fibroblasts were treated with 
cell medium supplemented with 5% FBS with/without the simultaneous addition of MG262 
(10 nM) for 24 h. Cells were then fixed/permeabilized in 70% ethanol and stained with 
propidium iodide, as indicated in Materials and Methods. DNA content was then measured by 
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FACS. Graphs show representative DNA profiles of 0% FBS-, 5% FBS- and MG262-treated 
fibroblasts. (B) Fibroblasts were treated with 5% FBS-supplemented medium with/without 
the simultaneous addition of MG262 (10 nM) for 22 h. Two hours before the end of this 
period the nucleoside 5-ethynyl-2´-deoxyuridine (EdU) was added to the cell cultures. Cells 
were then fixed in 70% ethanol, permeabilized with Triton X-100, and processed for the 
analysis of EdU incorporation into DNA by FACS, as indicated in Materials and Methods. 
Representative graphs of proliferating (Click-iT+) and non-proliferating cells of 0% FBS-, 5% 
FBS- and MG262-treated fibroblasts are shown. Data are representative of n= 6 (A) and n= 4 
(B) independent experiments from different patients. 
 
Figure 5. Effect of MG262 on cell cycle regulatory proteins in nasal fibroblasts. Fibroblasts 
were incubated with DMEM supplemented with 5% FBS with/without the simultaneous 
addition of MG262 (5, 10 and 50 nM) for different times (6 and 24 h). Cellular lysates were 
then obtained, electrophoresed on SDS-polyacrylamide gels, transferred to nitrocellulose 
membranes, and membranes processed for the analysis of cell cycle regulatory proteins by 
Western Blot. (A,B) Representative images of phosphorylated and total retinoblastoma (Rb) 
proteins in (A) time-course and (B) concentration-response experiments with MG262. (C) 
Quantification of cyclin D1 after 6 and 24 h of MG262 exposure. *p<0.05. (D,E) 
Quantification of p21 (upper graphs) and p27 (lower graphs) in (D) time-course and (E) 
concentration-response experiments with MG262. Bars show the median and whiskers the 
interquartile range of n= 7 independent experiments from different patients. *p<0.05, 
**p<0.01 and ***p<0.001 vs 5% FBS. 
 
Figure 6. Effect of MG262 on collagen mRNA expression in nasal fibroblasts. (A,B) Nasal 
mucosa and polyp fibroblasts were incubated with cell medium without FBS and MG262 for 
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1 h prior to either the addition (A) or not (B) of TGF-β (5 ng/ml) for 24 h. Total cellular RNA 
was then extracted and converted (1 μg) to cDNA, and the mRNA expression of collagens 
1α1, 1α2 and 3α1 was analyzed by real-time PCR and normalized to the RNA polymerase II 
constitutive gene. Graphs show the median (bars) and interquartile range (whiskers) of (A) n= 
7 (nasal mucosa) and n= 12 (nasal polyps) and (B) n= 5 independent experiments from 
different patients. *p<0.05, **p<0.01 and ***p<0.001 vs untreated; ††p<0.01 and 
†††p<0.001 vs TGF-β. (C) Fibroblasts were incubated with cell medium without FBS and 
MG262 (50 nM) for 1 h prior to the addition or not of TGF-β (5 ng/ml) for 24 h. Cellular 
lysates were then obtained, electrophoresed on SDS-polyacrylamide gels, transferred to 
nitrocellulose membranes, and membranes processed for the analysis of p-c-Jun, PPAR-γ, p53 
and β-actin by Western Blot. Images are representative of n= 3 independent experiments from 
different patients. 
 
Figure 7. Effect of MG262 on IL-6 and IL-8 production in nasal fibroblasts. (A,B) Nasal 
mucosa and polyp fibroblasts were incubated with cell medium supplemented with 10% 
csFBS in the absence or presence of (A) 5 to 500 nM of MG262, or (B) 10 μM of BMS-
345541 (IKK/NF-κB inhibitor), 20 μM of SP600125 (JNK inhibitor), 10 μM of SB203580 
(p38 MAPK inhibitor), 10 μM of U0126 (MEK1/2 inhibitor), or 1 μM of wortmannin 
(PI3K/Akt inhibitor) for 1 h prior to addition of IL-1β (10 ng/ml) for 4 h. IL-6 and IL-8 
production in supernatants was measured by ELISA. Graphs show the median (bars) and 
interquartile range (whiskers) of n= 5 (A) and n= 3 (B) independent experiments from 
different patients. **p<0.01 vs untreated; †p<0.05, ††p<0.01 and †††p<0.001 vs IL-β. (C) 
Fibroblasts were incubated with 10% csFBS-supplemented medium in the absence or 
presence of MG262 (500 nM) for 1 h prior to IL-1β stimulation (100 ng/ml) for 30 min. Cells 
were then fixed, permeabilized, incubated with anti-p65 antibody and visualized by 
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fluorescence microscopy. Representative images of p65 immunocytochemistry from n= 3 
independent experiments from different patients are shown. Bars, 25 μm. (D,E) Fibroblasts 
were incubated in the absence or presence of MG262 (500 nM) as indicated in C and then 
stimulated with IL-1β (10 ng/ml) for (D) 5 to 15 min or (E) 4 h. Cellular lysates were 
obtained and processed for Western Blot analysis of p-IκBα, p-p38, p-c-Jun and β-actin. 
Images are representative of n= 2 (D) and n= 3 (E) independent experiments from different 
patients. 
 
Figure 8. Effect of MG262 on the production of other pro-inflammatory mediators in nasal 
fibroblasts. Nasal mucosa and polyp fibroblasts were incubated with 10% csFBS-
supplemented medium in the absence or presence of 50 and 500 nM of MG262 for 1 h prior 
to addition of IL-1β (10 ng/ml) for 4 h. MCP-1, RANTES and GM-CSF production in 
supernatants was measured with Cytometric Bead Array Flex Sets by FACS. Graphs show the 
median (bars) and interquartile range (whiskers) of n= 5 independent experiments from 
different patients. *p<0.05 and **p<0.01 vs untreated; †p<0.05 and ††p<0.01 vs IL-β. 
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TABLES 
Table 1. Effect of MG262 on the cell cycle and DNA replication of nasal fibroblasts. 
Cell treatment G0/1 phase 
(n= 6) 
S phase 
(n= 6) 
G2/M phase 
(n= 6) 
DNA replicating 
cells (n= 4) 
0% FBS 92 (88.7-94.8) 1.9 (1.1-4.2) 5.3 (3.4-7.1) 4.7 (0.8-7.7) 
5% FBS 65.3 (50.2-76.8)** 13.3 (8.6-16.6)** 19.2 (13.8-34.3)* 25.8 (17.8-37.8)** 
MG262 (10 nM) 91.9 (86.5-95.3)† 2.1 (1-3.8)† 4.8 (2.6-8.1)†† 0.5 (0.2-2.6)††† 
 
Results expressed as median and interquartile range (%). *p< 0.05 and **p< 0.01 vs 0% FBS-
treated cells; †p< 0.05, ††p< 0.01, and †††p<0.001 vs 5% FBS-treated cells. 
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